National Longitudinal Cohort of Hematological Diseases

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Nov 19, 2020

Keywords

ClinConnect Summary

The National Longitudinal Cohort of Hematological Diseases study is looking to better understand various blood-related conditions, such as multiple myeloma, acute myeloid leukemia, and hemophilia, among others. This research aims to gather comprehensive information about how often these diseases occur, the factors that may increase the risk of developing them, the treatments that patients receive, their recovery outcomes, and the medical costs involved. By collecting data from patients diagnosed with these conditions since January 1, 2020, the study hopes to create a large database that can help improve care for people with blood diseases in China.

To participate in this study, individuals must have been diagnosed with one of the targeted blood disorders or received a bone marrow transplant at a participating hospital since the start date. Unfortunately, those who may not be able to provide long-term follow-up information or have serious health issues, substance addictions, or other safety concerns may not be eligible. Participants can expect to share their health information through questionnaires and will be followed over time to track their health progress. This is an important opportunity to contribute to research that could enhance treatment and care for patients with blood diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.
• Exclusion Criteria:
• • Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
• • Alcohol and drug addictions affect their ability to comply with study requirements.
• • According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.